RESUMEN
Numerous health legislations concerning child mortality, maternal health and life-threatening diseases such as polio and tuberculosis are crafted in the health sector of Pakistan. A critical assessment of health legislations points to their in-effective or sub-optimal implementation. By engaging with the concept of public law, there is a strong relationship of public health and health legislations. While the basic purpose of health legislations is to craft and enforce essential health legislations for improving public health, an examination of health legislations across Pakistan indicate an extensive health engagement which is facing certain challenges indicating traditional health practices, enforcement constraints arising due to political compulsions and complexities, and systematic problems in the health sector, reflecting issue of governance. Through focus group discussions and in-depth interviews held with policy-makers, senior health officials private health entities and parliamentarian tasks forces on millennium development goals, this study engages with health-sector legislations. In so doing, it focuses on the problematic health sector and interventions. It is observed that unless an overarching legislative framework and a shift from programmatic approach to a human rights approach is adopted, the targets of millennium development goals 4, 5 and 6 would remain off-track in Pakistan.
Asunto(s)
Salud Infantil/legislación & jurisprudencia , Objetivos , Salud de la Mujer/legislación & jurisprudencia , Adulto , Niño , Femenino , Derechos Humanos , Humanos , PakistánRESUMEN
BACKGROUND AND OBJECTIVES: IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent for induction therapy in renal transplantation. However, this remains controversial in deceased donor renal transplantation (DDRT) maintained on tacrolimus (TAC)/mycophenolic acid (MPA) with or without steroids. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied the United Network for Organ Sharing Registry for patients receiving DDRT from 2000 to 2012 maintained on TAC/MPA at transplantation hospital discharge (n=74,627) to compare outcomes of IL2-RA and other induction agents. We initially divided the cohort into two groups on the basis of steroid use at the time of discharge: steroid (n=59,010) versus no steroid (n=15,617). Each group was stratified into induction categories: IL2-RA, rabbit antithymocyte globulin (r-ATG), alemtuzumab, and no induction. The main outcomes were incidence of acute rejection within the first year and overall graft failure (defined as graft failure and/or death) post-transplantation. Propensity score (PS), specifically inverse probability of treatment weight, analysis was used to minimize selection bias caused by nonrandom assignment of induction therapies. RESULTS: Median (25th, 75th percentiles) follow-up times were 3.9 (1.1, 5.9) and 3.2 (1.1, 4.9) years for steroid and no steroid groups, respectively. Acute rejection within the first year and overall graft failure within 5 years of transplantation were more common in the no induction category (13.3%; P<0.001 and 28%; P=0.01, respectively) in the steroid group and the IL2-RA category (11.1%; P=0.16 and 27.4%; P<0.001, respectively) in the no steroid group. Compared with IL2-RA, PS-weighted and covariate-adjusted multivariable logistic and Cox analyses showed that outcomes in the steroid group were similar among induction categories, except that acute rejection was significantly lower with r-ATG (odds ratio [OR], 0.68; 95% confidence interval [95% CI], 0.62 to 0.74). In the no steroid group, compared with IL2-RA, odds of acute rejection with r-ATG (OR, 0.80; 95% CI, 0.60 to 1.00) and alemtuzumab (OR, 0.68; 95% CI, 0.53 to 0.88) were lower, and r-ATG was associated with better graft survival (hazard ratio, 0.86; 95% CI, 0.75 to 0.99). CONCLUSIONS: In DDRT, compared with IL2-RA induction, no induction was associated with similar outcomes when TAC/MPA/steroids were used. r-ATG seems to offer better graft survival over IL2-RA in steroid avoidance protocols.
Asunto(s)
Alemtuzumab/uso terapéutico , Suero Antilinfocítico/uso terapéutico , Rechazo de Injerto/epidemiología , Inmunosupresores/uso terapéutico , Quimioterapia de Inducción/métodos , Trasplante de Riñón/métodos , Esteroides/uso terapéutico , Adolescente , Adulto , Anciano , Femenino , Estudios de Seguimiento , Rechazo de Injerto/prevención & control , Supervivencia de Injerto , Humanos , Incidencia , Quimioterapia de Mantención/métodos , Masculino , Persona de Mediana Edad , Ácido Micofenólico/uso terapéutico , Puntaje de Propensión , Receptores de Interleucina-2/antagonistas & inhibidores , Sistema de Registros , Tacrolimus/uso terapéutico , Adulto JovenRESUMEN
Low-solute hyponatremia is a relatively uncommon entity of euvolemic hyponatremia. Classic cases were described in alcoholics as beer potomania, which is characterized by hyponatremia in the setting of low-solute intake due to heavy beer drinking. We report a case of low-solute hyponatremia in a nonalcoholic person who was given a solute load, and, subsequently, had excessive diuresis with the resultant rapid increase in serum sodium concentration.